GB0602778D0 - Novel compound - Google Patents

Novel compound

Info

Publication number
GB0602778D0
GB0602778D0 GBGB0602778.3A GB0602778A GB0602778D0 GB 0602778 D0 GB0602778 D0 GB 0602778D0 GB 0602778 A GB0602778 A GB 0602778A GB 0602778 D0 GB0602778 D0 GB 0602778D0
Authority
GB
United Kingdom
Prior art keywords
novel compound
novel
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB0602778.3A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Glaxo Group Ltd
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36119909&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=GB0602778(D0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Priority to GBGB0602778.3A priority Critical patent/GB0602778D0/en
Publication of GB0602778D0 publication Critical patent/GB0602778D0/en
Priority to ARP070100537A priority patent/AR059409A1/es
Priority to EA200801691A priority patent/EA016580B1/ru
Priority to HUE07704449A priority patent/HUE034315T2/en
Priority to SG201100933-9A priority patent/SG169404A1/en
Priority to CA2641769A priority patent/CA2641769C/en
Priority to CN2007800050282A priority patent/CN101379057B/zh
Priority to PE2007000135A priority patent/PE20071249A1/es
Priority to PE2010000996A priority patent/PE20110120A1/es
Priority to PCT/EP2007/051196 priority patent/WO2007090859A1/en
Priority to NZ570242A priority patent/NZ570242A/en
Priority to PL07704449T priority patent/PL1981872T3/pl
Priority to ES07704449.3T priority patent/ES2640226T3/es
Priority to PT77044493T priority patent/PT1981872T/pt
Priority to US11/672,536 priority patent/US7960551B2/en
Priority to LTEP07704449.3T priority patent/LT1981872T/lt
Priority to HRP20171304TT priority patent/HRP20171304T1/hr
Priority to KR20087022160A priority patent/KR101488691B1/ko
Priority to SI200731963T priority patent/SI1981872T1/sl
Priority to BRPI0707559A priority patent/BRPI0707559B8/pt
Priority to TW096104636A priority patent/TWI401251B/zh
Priority to EP07704449.3A priority patent/EP1981872B1/en
Priority to AU2007213767A priority patent/AU2007213767B2/en
Priority to DK07704449.3T priority patent/DK1981872T3/en
Priority to JP2008553758A priority patent/JP5616021B2/ja
Priority to JOP/2007/0037A priority patent/JO3389B1/ar
Priority to UAA200809940A priority patent/UA100364C2/ru
Priority to IL193103A priority patent/IL193103A/en
Priority to ZA200806782A priority patent/ZA200806782B/xx
Priority to NO20083425A priority patent/NO341343B1/no
Priority to MYPI20083025A priority patent/MY153656A/en
Priority to CR10227A priority patent/CR10227A/es
Priority to MA31228A priority patent/MA30273B1/fr
Priority to ARP160101036A priority patent/AR104288A2/es
Priority to CY20171100887T priority patent/CY1119238T1/el
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/16—Central respiratory analeptics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Pulmonology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Hydrogenated Pyridines (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
GBGB0602778.3A 2006-02-10 2006-02-10 Novel compound Ceased GB0602778D0 (en)

Priority Applications (35)

Application Number Priority Date Filing Date Title
GBGB0602778.3A GB0602778D0 (en) 2006-02-10 2006-02-10 Novel compound
JP2008553758A JP5616021B2 (ja) 2006-02-10 2007-02-08 ビフェニル−２−イルカルバミン酸１−［２−（２−クロロ−４−｛［（ｒ）−２−ヒドロキシ−２−（８−ヒドロキシ−２−オキソ−１，２−ジヒドロキノリン−５−イル）エチルアミノメチル］｝−５−メトキシフェニルカルバモイル）エチル］ピペリジン−４−イルエステルのコハク酸塩および肺疾患治療におけるその使用
JOP/2007/0037A JO3389B1 (ar) 2006-02-10 2007-02-08 ملح حمض سكسينيك من إستر لحمض باي فينيل-2-يل كارباميك 1-[2-(2-كلورو-4-{[(r) -2)- هيدوكسي-2-(8-هيدروكسي-2-أوكسو-1 ، 2-داي هيدرو كينولين -5- يل ) إثيل أمينوميثيل]} -5-ميثوكسي فينيل كاربامويل) إثيل] ببريدين-4-يل واستخدامه لعلاج الاضطرابات الرئوية)
LTEP07704449.3T LT1981872T (lt) 2006-02-10 2007-02-08 Bifenil-2-ilkarbamo rūgšties 1-[2-(2-chlor-4-{[(r)-2-hidroksi-2-(8-hidroksi-2-okso-1,2-dihidrochinolin-5-il)etilamino]metil]}-5-metoksifenilkarbamoil)etil]piperidin-4-ilo esterio gintaro rūgšties druska ir jos naudojimas plaučių susirgimų gydymui
SI200731963T SI1981872T1 (sl) 2006-02-10 2007-02-08 Sol jantarne kisline 1-(2-(2-kloro-4-(((R)-2-hidroksi-2-(8-hidroksi-2-okso-1,2-dihidrokinolin -5-il)etilamino)metil)-5-metoksifenilkarbamoil)etil)piperidin-4-il estra bifenil-2-ilkarbamske kisline in njena uporaba za zdravljenje pljučnih motenj
HUE07704449A HUE034315T2 (en) 2006-02-10 2007-02-08 Biphenyl-2-ylcarbamic acid 1- [2- (2-chloro-4 - {[(R) -2-hydroxy-2- (8-hydroxy-2-oxo-1,2-dihydroquinolin-5-yl) - succinic acid salt of ethylamino] methyl} -5-methoxyphenylcarbamoyl) ethyl] piperidin-4-yl ester and its use for the treatment of pulmonary disorders
SG201100933-9A SG169404A1 (en) 2006-02-10 2007-02-08 Succinic acid salt of biphenyl-2-ylcarbamic acid 1-[2-(2-chloro-4-{[(r)-2- hydroxy-2-(8-hydroxy-2-oxo-1,2-dihydroquinolin-5-yl) ethylamino]methyl]}-5- methoxyphenylcarbamoyl)ethyl] piperidin-4-yl ester and its use for the treatment of pulmonary disorders
CA2641769A CA2641769C (en) 2006-02-10 2007-02-08 Succinic acid salt of biphenyl-2-ylcarbamic acid 1-[2-(2-chloro-4-{[(r)-2-hydroxy-2-(8-hydroxy-2-oxo-1,2-dihydroquinolin-5-yl)ethylamino]methyl}-5-methoxyphenylcarbamoyl) ethyl] piperidin-4-yl ester and its use for the treatment of pulmonary disorders
CN2007800050282A CN101379057B (zh) 2006-02-10 2007-02-08 联苯-2-基氨基甲酸1-[2-(2-氯-4-{[(r)-2-羟基-2-(8-羟基-2-氧代-1,2-二氢喹啉-5-基)乙基氨基]甲基}-5-甲氧基苯基氨甲酰基)乙基]哌啶-4-基酯的琥珀酸盐及其治疗肺疾病的用途
PE2007000135A PE20071249A1 (es) 2006-02-10 2007-02-08 Sal de acido succinico de 1-[2-(2-cloro-4-{[(r)-2-hidroxi-2-(8-hidroxi-2-oxo-1,2-dihidroquinolin-5-il)etilamino]metil}-5-metoxifenilcarbamoil)etil]piperidin-4-il ester del acido bifenil-2-ilcarbamico
PE2010000996A PE20110120A1 (es) 2006-02-10 2007-02-08 Sal de acido succinico de 1-[2-(2-cloro-4-{[(r)-2-hidroxi-2-(8-hidroxi-2-oxo-1,2-dihidroquinolin-5-il)etilamino]metil}-5-metoxifenilcarbamoil)etil]piperidin-4-il ester del acido bifenil-2-ilcarbamico
PCT/EP2007/051196 WO2007090859A1 (en) 2006-02-10 2007-02-08 Succinic acid salt of biphenyl-2-ylcarbamic acid 1-[2-(2-chloro-4-{ [ (r)-2-hydroxy-2- (8-hydroxy-2-oxo-1, 2-dihydroquinolin-5-yl) eth ylaminoimethyl] } -5-methoxyphenylcarbamoyl) ethyl] piperidin-4-yl ester and its use for the treatment of pulmonary disorders
NZ570242A NZ570242A (en) 2006-02-10 2007-02-08 Succinic acid salt of biphenyl-2-ylcarbamic acid 1-[2-(2-chloro-4-{ [(R)-2-hydroxy-2-(8-hydroxy-2-oxo-1,2-dihydroquinolin-5-yl)ethylamino]methyl} -5-methoxyphenylcarbamoyl)ethyl]piperidin-4-yl ester and its use for the treatment of pulmonary disorders
PL07704449T PL1981872T3 (pl) 2006-02-10 2007-02-08 Sól kwasu bursztynowego estru 1-[2-(2-chloro-4-{[(r)-2-hydroksy-2-(8-hydroksy-2-okso-1,2-dihydrochinolin-5-ylo) ety-loaminometylo]}-5-metoksyfenylokarbamoilo)etylo]piperydyn-4-ylowego kwasu bifenyl-2-ilokarbaminowego i jego zastosowanie do leczenia zaburzeń czynności płuc
ES07704449.3T ES2640226T3 (es) 2006-02-10 2007-02-08 Sal de ácido succínico del éster 1-[2-(2-cloro-4-{[(R)-2-hidroxi-2-(8-hidroxi-2-oxo-1,2-dihidroquinolin-5-il)etilaminometil]}-5-metoxifenilcarbamoil)etil]piperidin-4-ílico del ácido bifenil-2-ilcarbámico y su uso para el tratamiento de trastornos pulmonares
PT77044493T PT1981872T (pt) 2006-02-10 2007-02-08 Sal de ácido succínico de éster 1-[2-(2-cloro-4-{[(r)-2-hidroxi-2-(8-hidroxi-2-oxo-1,2-di-hidroquinolin-5-il)etilamino]metil]}-5-metoxifenilcarbamoil)etil]piperidin-4-ílico de ácido bifenil-2-ilcarbâmico e a sua utilização para o tratamento de distúrbios pulmonares
US11/672,536 US7960551B2 (en) 2006-02-10 2007-02-08 Compound
ARP070100537A AR059409A1 (es) 2006-02-10 2007-02-08 Forma cristalina del succinato de 1-[2-(2-cloro-4-{[r-2-hidroxi-2-(8-hidroxi-2-oxo-1, 2-dihidroquinolin-5-il) etilamino] metil}-5- metoxifenilcarbamoil) etil] piperidin-4-il ester del acido bifenil-2-il-carbamico, una combinacion y una composicion farmaceutica que los contiene y el uso de la misma e
HRP20171304TT HRP20171304T1 (hr) 2006-02-10 2007-02-08 Sol s jantarnom kiselinom 1-[2-(2-klor-4-{[(r)-2-hidroksi-2-(8-hidroksi-2-okso-1,2-dihidrokinolin-5-il)etilaminometil]}-5-metoksifenilkarbamoil)etil]piperidin-4-ilnog estera bifenil-2-ilkarbaminske kiseline i njezina upotreba u liječenju plućnih poremećaja
KR20087022160A KR101488691B1 (ko) 2006-02-10 2007-02-08 비페닐-2-일카르밤산 1-〔2-（2-클로로-4-｛〔（ｒ）-2-히드록시-2-（8-히드록시-2-옥소-1,2-디히드로퀴놀린-5-일）에틸아미노〕메틸｝-5-메톡시페닐카르바모일）에틸〕피페리딘-4-일 에스테르의 석신산 염 및 이의 폐질환 치료를 위한 용도
EA200801691A EA016580B1 (ru) 2006-02-10 2007-02-08 Соль янтарной кислоты 1-[2-(2-хлор-4-{[(r)-2-гидрокси-2-(8-гидрокси-2-оксо-1,2-дигидрохинолин-5-ил)этиламино]метил}-5-метоксифенилкарбамоил)этил]пиперидин-4-илового эфира бифенил-2-илкарбаминовой кислоты и ее применение для лечения легочных расстройств
BRPI0707559A BRPI0707559B8 (pt) 2006-02-10 2007-02-08 polimorfo de forma i do sal de ácido succínico de 1- [2- (2- cloro- 4- {[(r)- 2- hidróxi- 2- (8- hidróxi- 2- oxo- 1,2- diidroquinolin- 5- il) etilamino] meti1]}- 5- metoxifenilcarbamoil) etil] piperidin- 4- il éster de ácido bifenil- 2- il- carbâmico, seu processo de preparo e usos
TW096104636A TWI401251B (zh) 2006-02-10 2007-02-08 新穎化合物
EP07704449.3A EP1981872B1 (en) 2006-02-10 2007-02-08 Succinic acid salt of biphenyl-2-ylcarbamic acid 1-[2-(2-chloro-4-{[ (r)-2-hydroxy-2- (8-hydroxy-2-oxo-1, 2-dihydroquinolin-5-yl) eth ylaminoimethyl]} -5-methoxyphenylcarbamoyl) ethyl]piperidin-4-yl ester and its use for the treatment of pulmonary disorders
AU2007213767A AU2007213767B2 (en) 2006-02-10 2007-02-08 Succinic acid salt of biphenyl-2-ylcarbamic acid 1-[2-(2-chloro-4-{ [ (R)-2-hydroxy-2- (8-hydroxy-2-oxo-1, 2-dihydroquinolin-5-yl) ethylaminoimethyl] } -5-methoxyphenylcarbamoyl) ethyl] piperidin-4-yl ester and its use for the treatment of pulmonary disorders
DK07704449.3T DK1981872T3 (en) 2006-02-10 2007-02-08 Succinic salt of biphenyl-2-ylcarbamic acid 1- [2- (2-chloro-4 - {[(r) -2-hydroxy-2- (8-hydroxy-2-oxo-1,2-dihydroquinolin-5-yl) (5-methoxyphenylcarbamoyl) ethyl] piperidin-4-yl ester and its use in the treatment of pulmonary diseases.
UAA200809940A UA100364C2 (xx) 2006-02-10 2007-08-02 Сукцинат біфеніл-2-ілкарбамінової кислоти 1-$2-(2-хлор-4-{$(r)-2-гідрокси-2-(8-гідроксі-2-оксо-1,2-дигідрохінолін-5-іл)етиламіно]метил]}-5-метоксифенілкарбамоїл)етил]піперидин-4-іл-естеру та його застосування для лікування легеневих розладів
IL193103A IL193103A (en) 2006-02-10 2008-07-29 Biphenyl succinic acid salt-2-ram-carboxylic acid 1- [2- (2-chloro-4 - {[(r) -2-hydroxy-2- (8-hydroxy-2-oxo-2,1-dihydroquinoline) (5-yl) ethylamino-methyl-5-methoxyphenyl-carbamoyl) -piperidine-4-yeast ester and a pharmaceutical composition comprising the above for the treatment of health disorders
ZA200806782A ZA200806782B (en) 2006-02-10 2008-08-05 Succinic acid salt of biphenyl-2-ylcarbamic acid 1-[2-(2-chloro-4{[R)-2-hydroxy-2-(8-hydroxy-2-oxo-1,2-dihydroquinolin-5-yl)ethylaminoimethyl]}-5-methoxyphenyl-carbamoyl) ethyl] piperidin-4-YL ester and its use for the treatment of pulmonary disorders
NO20083425A NO341343B1 (no) 2006-02-10 2008-08-05 Ravsyresalt av bifenyl-2-ylkarbaminsyre 1-[2-(2-klor-4-{[(R)-2-hydroksy-2-(8-hydroksy-2-okso-1,2-dihydrokinolin-5-yl)etylamino]metyl]}-5- metoksyfenylkarbamoyl)etyl]piperidin-4-yl-ester, farmasøytisk preparat som omfatter ravsyresaltet, dets anvendelse, fremgangsmåte for fremstilling derav samt kombinasjon derav med et antiinflammatorisk middel
MYPI20083025A MY153656A (en) 2006-02-10 2008-08-08 Succinc acid salt of biphenyl-2-ylcarbamic acid 1-[2-(2-chloro-4-{[(r)-2-hydroxy-2-(8-hydroxy-2-oxo-1,2-dihydroquinolin-5-yl) ethylamino]methyl]}-5-methoxyphenylcarbamyl)ethyl]piperidin-4-yl ester and its use for the treatment of pulmonary disorders
CR10227A CR10227A (es) 2006-02-10 2008-08-20 Sal de ácido succínico del éster 1-[2-(2-cloro-4-{[(R)-2-hidroxi-2-(8-hidroxi-2-oxo-1,2-dihidroquinolin-5-il)etilmino]metil}-5-metoxifenilcarbamoil)etil]piperidin-4-ílicodelácidobifenil2ilcarbámicoysuusoparaeltratamientodetrastornospulmonar
MA31228A MA30273B1 (fr) 2006-02-10 2008-09-10 Sel d'acide succinique de l'ester 1-{2-(2-chloro-4-{[(r)-2-hydroxy-2-oxo-1,2- dihydroquinolin-5-yl)methoxyphenylcarbamoyl)ethyl]piperidin-5-ylique de l'acide biphenyl-2-ylcarbamique et son utilisation pour le traitement de troubles pulmonaires.
ARP160101036A AR104288A2 (es) 2006-02-10 2016-04-15 Forma cristalina i de la sal del ácido succínico de 1-[2-(2-cloro-4-[(r)-2-hidroxi-2-(8-hidroxi-2-oxo-1,2-dihidroquinolin-5-il)etilamino]metil-5-metoxifenilcarbamoil)etil]piperidin-4-il éster del ácido bifenil-2-ilcarbámico, composiciones, combinaciones y procedimiento para su preparación
CY20171100887T CY1119238T1 (el) 2006-02-10 2017-08-22 Αλας ηλεκτρικου οξεος του 1-[2-(2-χλωρο-4-{[(r)-2-υδροξυ-2-(8-υδροξυ-2-οξο-1,2-διϋδροκινολιν-5-υλ)αιθυλαμινο]μεθυλ]}-5-μεθοξυφαινυκαρβαμοϋλ)αιθυλ]πιπεριδιν-4-υλ εστερα διφαινυλ-2-υλκαρβαμικου οξεος και χρηση αυτου για την θεραπεια πνευμονικων διαταραχων

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0602778.3A GB0602778D0 (en) 2006-02-10 2006-02-10 Novel compound

Publications (1)

Publication Number Publication Date
GB0602778D0 true GB0602778D0 (en) 2006-03-22

Family

ID=36119909

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB0602778.3A Ceased GB0602778D0 (en) 2006-02-10 2006-02-10 Novel compound

Country Status (33)

Country Link
US (1) US7960551B2 (enExample)
EP (1) EP1981872B1 (enExample)
JP (1) JP5616021B2 (enExample)
KR (1) KR101488691B1 (enExample)
CN (1) CN101379057B (enExample)
AR (2) AR059409A1 (enExample)
AU (1) AU2007213767B2 (enExample)
BR (1) BRPI0707559B8 (enExample)
CA (1) CA2641769C (enExample)
CR (1) CR10227A (enExample)
CY (1) CY1119238T1 (enExample)
DK (1) DK1981872T3 (enExample)
EA (1) EA016580B1 (enExample)
ES (1) ES2640226T3 (enExample)
GB (1) GB0602778D0 (enExample)
HR (1) HRP20171304T1 (enExample)
HU (1) HUE034315T2 (enExample)
IL (1) IL193103A (enExample)
JO (1) JO3389B1 (enExample)
LT (1) LT1981872T (enExample)
MA (1) MA30273B1 (enExample)
MY (1) MY153656A (enExample)
NO (1) NO341343B1 (enExample)
NZ (1) NZ570242A (enExample)
PE (2) PE20110120A1 (enExample)
PL (1) PL1981872T3 (enExample)
PT (1) PT1981872T (enExample)
SG (1) SG169404A1 (enExample)
SI (1) SI1981872T1 (enExample)
TW (1) TWI401251B (enExample)
UA (1) UA100364C2 (enExample)
WO (1) WO2007090859A1 (enExample)
ZA (1) ZA200806782B (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA022030B1 (ru) 2009-04-14 2015-10-30 Глаксо Груп Лимитед Способ получения 1-[2-(2-хлор-4-формил-5-метоксифенилкарбамоил)этил]пиперидин-4-илового эфира бифенил-2-илкарбаминовой кислоты
DK2599778T3 (en) 2009-04-23 2017-06-26 Theravance Respiratory Co Llc Diamide compounds with muscarinic receptor antagonist and beta-2 adrenergic receptor agonist activity
AU2015234331B2 (en) * 2009-04-23 2017-08-03 Theravance Biopharma R&D Ip, Llc Diamide compounds having muscarinic receptor antagonist and beta2 adrenergic receptor agonist activity
WO2011081937A1 (en) 2009-12-15 2011-07-07 Gilead Sciences, Inc. Corticosteroid-beta-agonist-muscarinic antagonist compounds for use in therapy
EP2386555A1 (en) 2010-05-13 2011-11-16 Almirall, S.A. New cyclohexylamine derivatives having beta2 adrenergic agonist and m3 muscarinic antagonist activities
ITRM20110083U1 (it) 2010-05-13 2011-11-14 De La Cruz Jose Antonio Freire Piastra per la costruzione di carrelli per aeroplani
AR083115A1 (es) 2010-09-30 2013-01-30 Theravance Inc Sales oxalato cristalinas de un compuesto diamida
CA2842276C (en) * 2011-08-02 2020-11-24 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Pharmaceutical composition of oxidised avidin suitable for inhalation
EP2592078A1 (en) 2011-11-11 2013-05-15 Almirall, S.A. New cyclohexylamine derivatives having beta2 adrenergic agonist and M3 muscarinic antagonist activities
HK1215166A1 (zh) * 2012-12-18 2016-08-19 Almirall, S.A. 具有β2肾上腺素激动剂及M3毒蕈碱拮抗剂活性的新型环己基和奎宁环基氨基甲酸酯衍生物
TWI643853B (zh) 2013-02-27 2018-12-11 阿爾米雷爾有限公司 同時具有β2腎上腺素受體促效劑和M3毒蕈鹼受體拮抗劑活性之2-氨基-1-羥乙基-8-羥基喹啉-2(1H)-酮衍生物之鹽類
TWI641373B (zh) 2013-07-25 2018-11-21 阿爾米雷爾有限公司 具有蕈毒鹼受體拮抗劑和β２腎上腺素受體促效劑二者之活性的２－胺基－１－羥乙基－８－羥基喹啉－２（１Ｈ）－酮衍生物之鹽
TW201517906A (zh) 2013-07-25 2015-05-16 Almirall Sa 含有ｍａｂａ化合物和皮質類固醇之組合
TW201617343A (zh) 2014-09-26 2016-05-16 阿爾米雷爾有限公司 具有β２腎上腺素促效劑及Ｍ３蕈毒拮抗劑活性之新穎雙環衍生物
GB201500447D0 (en) * 2015-01-12 2015-02-25 Glaxosmithkline Ip Dev Ltd Novel Combination Product
CN106632257B (zh) * 2016-12-15 2019-02-12 上海市奉贤区中心医院 Gsk961081及其中间体的合成方法
US11484531B2 (en) 2018-08-30 2022-11-01 Theravance Biopharma R&D Ip, Llc Methods for treating chronic obstructive pulmonary disease

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4022776A (en) 1974-01-31 1977-05-10 Otsuka Pharmaceutical Company Limited 5-[1-Hydroxy-2-(substituted-amino)]ethyl-8-hydroxycarbostyril derivatives
DE3134590A1 (de) 1981-09-01 1983-03-10 Boehringer Ingelheim KG, 6507 Ingelheim Neue benzo-heterocyclen
US4460581A (en) 1982-10-12 1984-07-17 Boehringer Ingelheim Kg (1-Hydroxy-2-amino-alkyl)-substituted benzoxazinones and benzoxazolinones
ZW6584A1 (en) 1983-04-18 1985-04-17 Glaxo Group Ltd Phenethanolamine derivatives
US4894219A (en) 1988-03-29 1990-01-16 University Of Florida Beta-agonist carbostyril derivatives, assay method and pharmacological composition
DK443489D0 (da) 1989-09-08 1989-09-08 Ferrosan As Substituerede urinstofforbindelser, deres fremstilling og anvendelse
SK116394A3 (en) 1992-03-31 1995-04-12 Glaxo Group Ltd Substituted phenylcarbamates and ureas
CA2123728A1 (en) 1993-05-21 1994-11-22 Noriyoshi Sueda Urea derivatives and their use as acat inhibitors
AU7545894A (en) 1993-09-02 1995-03-22 Yamanouchi Pharmaceutical Co., Ltd. Carbamate derivative and medicine containing the same
AU685225B2 (en) 1994-02-10 1998-01-15 Yamanouchi Pharmaceutical Co., Ltd. Novel carbamate derivative and medicinal composition containing the same
US6130232A (en) 1995-10-13 2000-10-10 Banyu Pharmaceutical Coaltd Substituted piperidine derivatives as muscarinic M3 receptor antagonists
PE92198A1 (es) 1996-08-01 1999-01-09 Banyu Pharma Co Ltd Derivados de 1,4-piperidina disustituida que contienen fluor
US6040344A (en) 1996-11-11 2000-03-21 Sepracor Inc. Formoterol process
JP2002508366A (ja) 1997-12-12 2002-03-19 スミスクライン・ビーチャム・パブリック・リミテッド・カンパニー キノリンピペラジンおよびキノリンピペリジン誘導体、それらの製造方法、ならびに複合的５−ｈｔ１ａ、５−ｈｔ１ｂおよび５−ｈｔ１ｄ受容体アンタゴニストとしてのそれらの用途
US6541669B1 (en) 1998-06-08 2003-04-01 Theravance, Inc. β2-adrenergic receptor agonists
WO1999064043A1 (en) 1998-06-08 1999-12-16 Advanced Medicine, Inc. Muscarinic receptor antagonists
US6713651B1 (en) 1999-06-07 2004-03-30 Theravance, Inc. β2-adrenergic receptor agonists
US6693202B1 (en) 1999-02-16 2004-02-17 Theravance, Inc. Muscarinic receptor antagonists
GB9913083D0 (en) 1999-06-04 1999-08-04 Novartis Ag Organic compounds
US6593497B1 (en) 1999-06-02 2003-07-15 Theravance, Inc. β2-adrenergic receptor agonists
MXPA02005596A (es) 1999-12-07 2004-09-10 Theravance Inc Derivados de carbamato con actividad antagonista para el rerceptor muscarinico.
UA73543C2 (uk) 1999-12-07 2005-08-15 Тераванс, Інк. Похідні сечовини, фармацевтична композиція та застосування похідного при приготуванні лікарського засобу для лікування захворювання, яке опосередковується мускариновим рецептором
UA73965C2 (en) 1999-12-08 2005-10-17 Theravance Inc b2 ADRENERGIC RECEPTOR ANTAGONISTS
AU2930501A (en) * 2000-01-07 2001-07-24 Transform Pharmaceuticals, Inc. High-throughput formation, identification, and analysis of diverse solid-forms
BR0111440A (pt) 2000-06-05 2003-06-03 Altana Pharma Ag Compostos eficazes como agonistas do (beta)2-adrenorreceptor bem como inibidores de pde4
AU2002228015B2 (en) 2000-12-22 2007-08-23 Almirall, S.A. Quinuclidine carbamate derivatives and their use as M3 antagonists
GB0103630D0 (en) 2001-02-14 2001-03-28 Glaxo Group Ltd Chemical compounds
US20030018019A1 (en) 2001-06-23 2003-01-23 Boehringer Ingelheim Pharma Kg Pharmaceutical compositions based on anticholinergics, corticosteroids and betamimetics
TWI249515B (en) 2001-11-13 2006-02-21 Theravance Inc Aryl aniline beta2 adrenergic receptor agonists
US6653323B2 (en) 2001-11-13 2003-11-25 Theravance, Inc. Aryl aniline β2 adrenergic receptor agonists
PL213489B1 (pl) 2002-04-12 2013-03-29 Boehringer Ingelheim Pharma Kompozycje farmaceutyczne zawierajace betamimetyk i nowy lek antycholinergiczny oraz zastosowanie kompozycji
JP2005527618A (ja) 2002-05-28 2005-09-15 セラヴァンス インコーポレーテッド アルコキシアリールβ２アドレナリン作動性レセプターアゴニスト
GB0217225D0 (en) 2002-07-25 2002-09-04 Glaxo Group Ltd Medicinal compounds
AR040779A1 (es) 2002-08-06 2005-04-20 Glaxo Group Ltd Compuesto de tiazol anilina su uso para preparar una formulacion farmaceutica dicha formulacion recipiente que la contiene y dispositivo adaptado para la administracion intranasal de la formulacion
PE20040950A1 (es) * 2003-02-14 2005-01-01 Theravance Inc DERIVADOS DE BIFENILO COMO AGONISTAS DE LOS RECEPTORES ADRENERGICOS ß2 Y COMO ANTAGONISTAS DE LOS RECEPTORES MUSCARINICOS
JP4767842B2 (ja) 2003-04-01 2011-09-07 セラヴァンス， インコーポレーテッド β２アドレナリン作用性レセプターアゴニスト活性およびムスカリン性レセプターアンタゴニスト活性を有するジアリールメチル化合物および関連化合物
US7358244B2 (en) 2003-05-28 2008-04-15 Theravance, Inc. Azabicycloalkane compounds
CN100569760C (zh) 2003-11-21 2009-12-16 施万制药 具有β2肾上腺素能受体激动剂和毒蕈碱性受体拮抗剂活性的化合物
WO2005080375A1 (en) 2004-02-13 2005-09-01 Theravance, Inc. Crystalline form of a biphenyl compound
JP2008510014A (ja) 2004-08-16 2008-04-03 セラヴァンス， インコーポレーテッド β２アドレナリン作用性レセプターアゴニスト活性およびムスカリン性レセプターアンタゴニスト活性を有する化合物
TWI374883B (en) * 2004-08-16 2012-10-21 Theravance Inc Crystalline form of a biphenyl compound
US7569586B2 (en) 2004-08-16 2009-08-04 Theravance, Inc. Compounds having β2 adrenergic receptor agonist and muscarinic receptor antagonist activity

Also Published As

Publication number Publication date
AU2007213767A1 (en) 2007-08-16
SI1981872T1 (sl) 2017-10-30
BRPI0707559B1 (pt) 2021-01-12
CA2641769A1 (en) 2007-08-16
US20070281971A1 (en) 2007-12-06
KR101488691B1 (ko) 2015-02-02
AR059409A1 (es) 2008-04-09
ES2640226T3 (es) 2017-11-02
EP1981872A1 (en) 2008-10-22
WO2007090859A1 (en) 2007-08-16
TW200800948A (en) 2008-01-01
EA200801691A1 (ru) 2009-02-27
HRP20171304T1 (hr) 2017-10-20
IL193103A0 (en) 2009-02-11
EP1981872B1 (en) 2017-06-21
JP5616021B2 (ja) 2014-10-29
DK1981872T3 (en) 2017-09-11
SG169404A1 (en) 2011-03-30
JO3389B1 (ar) 2019-03-13
MY153656A (en) 2015-03-13
CN101379057B (zh) 2013-02-13
LT1981872T (lt) 2017-09-11
CR10227A (es) 2008-10-29
AU2007213767B2 (en) 2012-04-26
CN101379057A (zh) 2009-03-04
BRPI0707559A8 (pt) 2019-01-29
NO20083425L (no) 2008-09-09
AR104288A2 (es) 2017-07-12
CY1119238T1 (el) 2018-02-14
NO341343B1 (no) 2017-10-16
CA2641769C (en) 2014-02-04
ZA200806782B (en) 2009-10-28
MA30273B1 (fr) 2009-03-02
US7960551B2 (en) 2011-06-14
EA016580B1 (ru) 2012-06-29
UA100364C2 (xx) 2012-12-25
HUE034315T2 (en) 2018-02-28
JP2009526018A (ja) 2009-07-16
IL193103A (en) 2013-06-27
NZ570242A (en) 2011-09-30
BRPI0707559B8 (pt) 2021-05-25
PE20110120A1 (es) 2011-03-08
PE20071249A1 (es) 2008-01-16
BRPI0707559A2 (pt) 2011-05-10
TWI401251B (zh) 2013-07-11
KR20080114723A (ko) 2008-12-31
PT1981872T (pt) 2017-09-13
PL1981872T3 (pl) 2017-11-30

Similar Documents

Publication Publication Date Title
ZA200808639B (en) Oxadiazolidinedione compound
EP2034838A4 (en) NOVEL CONNECTIONS
EP2032142A4 (en) NOVEL CONNECTIONS
EP2000469A4 (en) ACYLAMINOPIPERIDINVERBINDUNG
EP1981596A4 (en) NEW CONNECTIONS
GB0602778D0 (en) Novel compound
EP1981900A4 (en) NEW COMPOUNDS
GB0607096D0 (en) Compound
GB0603550D0 (en) Novel compounds
GB0605462D0 (en) Novel compounds
EP2031965A4 (en) NEW COMPOUNDS
GB0604142D0 (en) Compound
GB0607892D0 (en) Novel compounds
GB0600483D0 (en) Novel compounds
GB0607840D0 (en) Novel compounds
GB0618263D0 (en) Compound
GB0608452D0 (en) Novel compounds
GB0625043D0 (en) Novel compound
GB0606932D0 (en) Compound
GB0607251D0 (en) Compound
GB0615531D0 (en) Compound
GB0615464D0 (en) Compound
GB0603894D0 (en) Compound
GB0608455D0 (en) Novel compounds
GB0607353D0 (en) Novel Compounds

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)